The company has launched the product in 10ml and 3ml vials, Biocon said.
"Biocon is committed to developing affordable Insulin based therapies to manage this disease burden... It is our endeavour to play a key role in combating diabetes world over," Biocon chairman and managing director Kiran Mazumdar Shaw said.
